Future Treatments for NIDS
With the explosion of neuro-immune diseases, we face a crisis today like we have never experienced before. We do not have the luxury of leisurely researching all of the different parts of this disease process and hoping to find a cure in another 10 or 20 years. We are already at a point where our society is in grave trouble coping with this epidemic, and it will only get worse as we have to care for increasing numbers of adults with autism, as well as huge numbers with Alzheimer’s and other related disorders.
Switching Focus: The Medical Community’s Wake-Up Call
Now is the time to initiate a medical focus on children with NIDS—“throwing the switch” that recognizes these children are ill and must be treated with appropriate medical interventions, just as a physician would treat a child suffering from diabetes or cancer. Only then can medical protocols, such as the Goldberg Approach™, become expected and available now. It’s paramount that we move as fast as we can toward treatments for these diseases. Recognition of all NIDS conditions as medical (not developmental or psychological) disease by the American Academy of Pediatrics is a first critical step. Hearings need to be held regarding the reclassification of NIDS-related disorders. Until this occurs, there will not be an urgent pharmaceutical and research focus on finding medicines to treat this dysfunction, as there was for polio and other medical diseases/epidemics of the past.
Specialists in the field of pediatrics, pediatric immunology, pediatric infectious disease, pediatric neurology, and pediatric endocrinology (more secondary than root cause) must join forces to do research and clinical trials aimed at treating the root causes of “autism” and other NIDS disorders in children. Researchers working in isolation on individual pieces of the medical puzzle might take decades more to find a treatment. If used properly, new agents called immune modulators, currently in the developmental pipeline, potentially could normalize the immune system and reduce dependence on other combinations of medicines. At this time, immune modulators are not slated for medical research in children, especially in relation to NIDS conditions, as many of these conditions wrongly continue to be defined as developmental delays or disorders.